Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20779509 | 0.89 | KDM1A (0.52) | KDM1ABRD4GPR35GRIK1GRIA2 | |
| SCHEMBL20766338 | 0.86 | KDM1A (0.50) | KDM1ABRD4GPR35GRIK1GRIA2 | |
| SCHEMBL25788936 | 0.84 | KDM1A (0.46) | KDM1ABRD4GPR35GRIK1GRIA2 | |
| SCHEMBL20779552 | 0.79 | KDM1A (0.44) | KDM1AGPR35GRIK1GRIA2KMT2A | |
| SCHEMBL20767240 | 0.79 | BRD4 (0.52) | BRD4PTGS2KMT2AYAP1PTGS1 | |
| SCHEMBL20779612 | 0.77 | BRD4 (0.43) | KDM1ABRD4GPR35GRIK1GRIA2 | |
| SCHEMBL20766548 | 0.76 | BRD4 (0.49) | BRD4PTGS2KMT2APTGS1 | |
| SCHEMBL20766229 | 0.76 | KDM1A (0.43) | KDM1ABRD4GPR35GRIK1GRIA2 | |
| SCHEMBL29901795 | 0.75 | BRD4 (0.55) | BRD4PTGS2 | |
| SCHEMBL20766946 | 0.75 | BRD4 (0.55) | BRD4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3691623-B1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192865-B2 | Benzosulfonyl compounds | YAP1, TEAD2, TEAD1 | KDM1A 391/4885BRD4 7/4885PTGS2 2196/4885 |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | YAP1, TEAD2, TEAD1 | KDM1A 391/4885BRD4 7/4885PTGS2 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.